News

Aclasta receives marketing authorisation

Pharmaceutical Executive Europe - Jun 30, 2005

Novartis Pharma AG has announced that Aclasta has been granted Marketing Authorization by the European Commission for the treatment of Paget's disease of the bone in all 25 European member states. This represents the first approval for Aclasta.

Consensus on metabolic syndrome to widen market for new drugs

Pharmaceutical Executive Europe - Jun 30, 2005

Although lifestyle interventions are the preferred first line treatment, drug therapy is needed by most patients.

Mergers and Acquisitions

Pharmaceutical Executive Europe - Jun 30, 2005

Business & Decision, the European consulting and data engineering company, has acquired a majority share in ME9taphora, a French consultancy company specializing in change relating to the implementation of new IT platforms. This acquisition enables Business & Decision to strengthen its position as a leading consultancy organization and to expand its offering to large enterprises beyond that of financial management.

Looking for a new home?

Pharmaceutical Executive Europe - Jun 30, 2005

Up to 1000 new skilled jobs could be created on the former GlaxoSmithKline site in Liverpool (UK). Knight Frank and BE Group acted for New Capital Developments in the A36.4 million (~?9.6 million) deal to purchase the factory site, which is a mixed use environment including office buildings, laboratory and pharmaceutical specialist space, R&D space, manufacturing areas, warehousing and development land.

Cancer Findings at ASCO

Pharmaceutical Executive Europe - Jun 30, 2005

The 41st annual meeting of the American Society of Clinical Oncology (ASCO) was held in May in Orlando, Florida (USA). This meeting is considered to be the premier educational and scientific event in the oncology community, and attracted more than 25000 doctors, nurses, patients and drug company employees. At the event, several companies presented recent developments in their clinical trials. Presentations included

Guidance for IND Studies

Pharmaceutical Executive Europe - Jun 30, 2005

The Center for Drug Evaluation and Research (CDER) at FDA has released a draft guidance document entitled Guidance for Industry, Investigators and Reviewers: Exploratory IND (investigational new drug) Studies.